Phase 3, double-blind, placebo-controlled, multicenter, randomized study to evaluate the efficacy and safety of ORMD 0801 in patients with type 2 diabetes mellitus with inadequate glycemic control with controlled diet alone or with controlled diet and hypoglycemic agents in monotherapy.